WanBangDe Pharmaceutical Group Co.,Ltd.   Report issue

For profit Phase 1 Phase 4
Founded: Wenling China (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2018
NCT03483779
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Wanbangde Pharmaceutical Group Co., LTD | WanBangDe Pharmaceutical Group Co.,Ltd.

Active Ingredients

Drugs in Phase 4 Trials (2)

ginkgo biloba (2 trials)

huperzine a (1 trial)

Drugs in Phase 1 Trials (1)

bromhexine (2 trials)

Drugs in Other Trials (3)

favipiravir (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

umifenovir (Arbidol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angina Pectoris (Phase 4)

Angina, Stable (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Heart Diseases (Phase 4)

Myocardial Ischemia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 6